NGNE vs. WVE, VERV, PAHC, AKBA, COLL, NTLA, PHVS, CRMD, RCUS, and SYRE
Should you be buying Neurogene stock or one of its competitors? The main competitors of Neurogene include WAVE Life Sciences (WVE), Verve Therapeutics (VERV), Phibro Animal Health (PAHC), Akebia Therapeutics (AKBA), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Pharvaris (PHVS), CorMedix (CRMD), Arcus Biosciences (RCUS), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
Neurogene vs. Its Competitors
Neurogene (NASDAQ:NGNE) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, dividends, valuation and earnings.
In the previous week, Neurogene had 5 more articles in the media than WAVE Life Sciences. MarketBeat recorded 7 mentions for Neurogene and 2 mentions for WAVE Life Sciences. Neurogene's average media sentiment score of 0.15 beat WAVE Life Sciences' score of 0.00 indicating that Neurogene is being referred to more favorably in the media.
Neurogene has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, WAVE Life Sciences has a beta of -1.01, indicating that its stock price is 201% less volatile than the S&P 500.
52.4% of Neurogene shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 11.6% of Neurogene shares are held by company insiders. Comparatively, 29.1% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Neurogene has higher earnings, but lower revenue than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.
Neurogene's return on equity of -36.16% beat WAVE Life Sciences' return on equity.
Neurogene currently has a consensus price target of $46.17, indicating a potential upside of 130.32%. WAVE Life Sciences has a consensus price target of $20.50, indicating a potential upside of 194.12%. Given WAVE Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe WAVE Life Sciences is more favorable than Neurogene.
Summary
Neurogene beats WAVE Life Sciences on 8 of the 15 factors compared between the two stocks.
Get Neurogene News Delivered to You Automatically
Sign up to receive the latest news and ratings for NGNE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Neurogene Competitors List
Related Companies and Tools
This page (NASDAQ:NGNE) was last updated on 7/4/2025 by MarketBeat.com Staff